The Numbers Don't Lie: Monsanto Ahead of Earnings

The video discusses Bayer's acquisition of Monsanto, highlighting the need for antitrust approval in 30 jurisdictions. The deal would create the largest producer of pesticides and genetically modified seeds. Market conditions have led to consolidation in crop chemicals, and investors are skeptical, with Monsanto's stock below Bayer's offer. Financial performance shows weakness in Bayer's AG Division, and there's concern about Bayer's shift from pharma. Monsanto forecasts earnings growth in 2017, driven by Intacta and Roundup sales.

What is the primary concern regarding the Monsanto-Bayer deal?

• The potential job losses in the agricultural sector

• The need for antitrust approval in multiple jurisdictions

• The environmental impact of genetically modified seeds

• The deal's impact on global pesticide prices

What has led to the consolidation in the crop chemicals market?

• High demand for organic products

• Increased government regulations

• Technological advancements in agriculture

• Tough market conditions and low crop prices

How do investors feel about the Monsanto-Bayer tie-up?

• They are supportive of the consolidation

• They are indifferent to the merger

• They are skeptical and concerned about the deal

• They are optimistic about the potential profits

What change is expected in Bayer's business structure if the deal goes through?

• Bayer will exit the crop science market

• Pharmaceuticals will be the main focus

• Crop science will replace healthcare as the largest division

• Healthcare will become the largest division

What is Monsanto's forecast for fiscal 2017?

• A shift in focus to new product development

• A return to earnings growth fueled by Intacta and Roundup sales

• Stable earnings with no significant growth

• A decline in earnings due to market conditions